Data from EMC - Curated by Toby Galbraith - Last updated 10 August 2017

Licensing authority

EMA (European Medicines Agency)


Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).

Full Prescribing information

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Airway Disease

The Airway Disease Learning Zone is an area where you can access the information about VisionAir and the upcoming live broadcast. A video presentation will be available from EAACI 2017 entitled 'Personalising Clinical Management in Severe Asthma'. The Inhalation Technology page features a video presentation from the live broadcast.

Visit Airway Disease

Allergic Rhinitis

Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.

Visit Allergic Rhinitis

Related Content

More information

Category Value
Agency product number EMEA/H/C/004257
Orphan designation No
Date First Approved 17-07-2017
Type Medicinal product subject to medical prescription
Marketing authorisation holder Chiesi Farmaceutici S.p.A.